Chinese exec fined for insider trading

Share this:

The board chairman of Chinese pharmaceutical company Hunan Fangsheng Pharmaceutical Co., Ltd has been fined 600,000 yuan. (~€77,000/~$91,000) in an insider trading case. Chinese officials started investigating the company in June 2019 following a rise in Fangshen shares the previous April when the company announced it had signed a cooperation agreement with the government of Huize County, Yunnan, to develop hemp farming and processing operations. The company later admitted in a subsequent announcement that the project was still in the planning phase and faced uncertainty, causing Fangshen’s stock to fall sharply. 

Recent Posts

Czech president expected to sign law raising THC limit to 1.0%

Czech President Miloš Zeman is expected to sign a bill that would set the limit…

September 17, 2021

Plastics startup off to fast start after raising $1 million via crowdfunding

Startup Canadian Industrial Hemp Corporation (CIHC) said it has raised more than $1 million of…

September 16, 2021

Hemp takes a foothold in grain, fiber in South Dakota’s first year

South Dakota farmers are harvesting hemp on 1,600 acres in 2021, and state officials say…

September 15, 2021

Biotech processes can drill down on cannabinoids, report suggests

Biotechnological production processes can unveil pharmacological profiles and potential effects of cannabinoids that are present…

September 14, 2021

Ongoing troubles over licensing lead to another arrest in Portugal

Prominent hemp entrepreneur and activist Hugo Monteiro was arrested on drug charges in Portugal last…

September 13, 2021

Opponents of California law say they were ‘tricked’ on smokable hemp

Opponents of a controversial hemp bill that awaits California Gov. Gavin Newsom's signature say final…

September 10, 2021